首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   60615篇
  免费   6936篇
  国内免费   2441篇
耳鼻咽喉   232篇
儿科学   459篇
妇产科学   487篇
基础医学   1979篇
口腔科学   637篇
临床医学   6617篇
内科学   3606篇
皮肤病学   515篇
神经病学   843篇
特种医学   1229篇
外国民族医学   3篇
外科学   2586篇
综合类   15123篇
现状与发展   9篇
一般理论   23篇
预防医学   5064篇
眼科学   300篇
药学   6552篇
  253篇
中国医学   22249篇
肿瘤学   1226篇
  2024年   546篇
  2023年   1555篇
  2022年   2652篇
  2021年   3491篇
  2020年   3621篇
  2019年   2438篇
  2018年   2017篇
  2017年   2744篇
  2016年   2693篇
  2015年   2461篇
  2014年   5947篇
  2013年   4806篇
  2012年   5201篇
  2011年   5201篇
  2010年   4268篇
  2009年   3214篇
  2008年   2696篇
  2007年   2853篇
  2006年   2207篇
  2005年   1799篇
  2004年   1406篇
  2003年   1154篇
  2002年   871篇
  2001年   802篇
  2000年   652篇
  1999年   511篇
  1998年   362篇
  1997年   311篇
  1996年   224篇
  1995年   207篇
  1994年   180篇
  1993年   125篇
  1992年   119篇
  1991年   112篇
  1990年   72篇
  1989年   60篇
  1988年   51篇
  1987年   50篇
  1986年   35篇
  1985年   52篇
  1984年   48篇
  1983年   27篇
  1982年   27篇
  1981年   27篇
  1980年   29篇
  1979年   14篇
  1978年   12篇
  1977年   12篇
  1976年   8篇
  1975年   8篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
941.
Background:Epilepsy is 1 of the common neurodevelopmental diseases. It can affect about 0.5% to 1.0% of the population regardless of their race and social class. Despite the development of a wide range of treatments, there remaining about one-third of patients still experience seizures. Chinese herbal compounds containing scorpion (CHCCS) have shown an outstanding curative effect on nerve protection and epilepsy. But there''s no study to assess its clinical efficacy and safety.Methods:Each data of CHCCS in treating epilepsy from related English and Chinese databases will be searched. The primary outcome is the efficacy of the CHCCS on epilepsy. And the secondary outcomes include recurrence rate and side effects. The risk of bias will be assessed, and RevMan5.3 and Stata14.0 will be performed for meta-analysis. Finally, we will assess the level of the resulting evidence.Results:The results of the study will be combined with current evidence and published in a peer-reviewed journal.Conclusions:This study will specifically investigate the effectiveness and safety of CHCCS in treating epilepsy.INPLASY registration number:INPLASY202120056.  相似文献   
942.
943.
Background:Myasthenia gravis (MG) is an archetypal autoimmune disorder. The conventional treatments for this disease are drugs, plasma exchange, surgical, and so on. However, this disease is difficult to cure. A mass of studies revealed that the external treatment of traditional Chinese medicine (TCM) for MG is a safe and economical approach. The present study conducted a meta-analysis to compare TCM external treatment combined with modern medicine with modern medicine for MG, in order to determine which TCM external treatment intervention has the best relative efficacy, safety, and provide the best evidence for clinical practice.Methods:PubMed, Cochrane Library, EMBASE, Web of Science, Springer, China National Knowledge Infrastructure (CNKI), Wan-fang database, VIP Chinese Science and Technique Journals Database, the Chinese Bio Medical Database (CBM), and Baidu Scholar were searched. The time of publication was limited from inception to February 28, 2021. Two reviewers independently searched for the selected articles and extract the data. The RevMan V.5.3 statistical software (Cochrane Collaboration) and Stata V.16.0 software were used to conduct the meta-analysis.Results:The results of the systematic review and meta-analysis will be published in a peer-reviewed journal.Conclusion:The present study provides a protocol that can be used in the systematic review and meta-analysis, with the intent to inform professionals on the external treatment of TCM for MG. These would lead to investigations on the use of the most external treatment of TCM for MG.Trial registration number:INPLASY202110083  相似文献   
944.
945.
946.
In this second of a 5-part Focus Seminar series, we focus on precision medicine in the context of vascular disease. The most common vascular disease worldwide is atherosclerosis, which is the primary cause of coronary artery disease, peripheral vascular disease, and a large proportion of strokes and other disorders. Atherosclerosis is a complex genetic disease that likely involves many hundreds to thousands of single nucleotide polymorphisms, each with a relatively modest effect for causing disease. Conversely, although less prevalent, there are many vascular disorders that typically involve only a single genetic change, but these changes can often have a profound effect that is sufficient to cause disease. These are termed “Mendelian vascular diseases,” which include Marfan and Loeys-Dietz syndromes. Given the very different genetic basis of atherosclerosis versus Mendelian vascular diseases, this article was divided into 2 parts to cover the most promising precision medicine approaches for these disease types.  相似文献   
947.
948.
949.
950.
What constitutes clinical reasoning is a disputed subject regarding the processes underlying accurate diagnosis, the importance of patient‐specific versus population‐based data, and the relation between virtue and expertise in clinical practice. In this paper, I present a model of clinical reasoning that identifies and integrates the processes of diagnosis, prognosis, and therapeutic decision making. The model is based on the generalized empirical method of Bernard Lonergan, which approaches inquiry with equal attention to the subject who investigates and the object under investigation. After identifying the structured operations of knowing and doing and relating these to a self‐correcting cycle of learning, I correlate levels of inquiry regarding what‐is‐going‐on and what‐to‐do to the practical and theoretical elements of clinical reasoning. I conclude that this model provides a methodical way to study questions regarding the operations of clinical reasoning as well as what constitute significant clinical data, clinical expertise, and virtuous health care practice.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号